ALXN News and Press, Alexion Pharmaceuticals Inc. From 01/27/21

Having overcome business challenges presented by the COVID-19 pandemic, the stock of Alexion Pharmaceuticals (ALXN) has been hitting new highs. We think it may be wise to bet on the stock now because this company has been receiving multiple regulatory approvals for its products. Headquart...

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2020 before the US financial markets open on February 4, 2021. Given the recently announced agreement to be acquire...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. 2020 was a year of monumental progress in renewable energ...

2020 was a busy year for global healthcare with unprecedented efforts to develop vaccines, treatments, and diagnostics for COVID-19. Deal flow in the sector continued to gain momentum in 2020, with M&A transactions and product licensing deals totalling five-year highs as large-cap...

The stock market recovered and forged ahead at an impressive pace after a correction last March. Observers now note that broader market indexes are currently trading at their all-time high levels and could possibly take a breather in the near term. We think a market pullback could present an ...

Alexion Pharmaceuticals (ALXN) announces the decision to pause further enrollment in the global Phase 3 study of ULTOMIRIS (ravulizumab-cwvz) in adults with severe COVID-19 requiring mechanical ventilation.This decision is based on the recommendation of an independent data monitorin...

– Independent data monitoring committee recommends pausing study enrollment due to lack of efficacy in pre-specified interim analysis – – Company will conduct further analysis of trial data to determine next steps – – No new safety fi...

IQVIA demonstrates a strong sequential growth pattern, in near recovery to pre-pandemic volumes. Management have reinstated the buyback program, with ~$1 billion in authorization, and look set on acquisition targeting across FY2021. We feel shares are worth ~$197 at this point, an...

After AstraZeneca ([[AZN]] -0.6%) splashed out $39B for Alexion ([[ALXN]] -0.4%) to expand its immunology presence, the transaction paved way for naturally following questions about whether it was justified. Now, ALXN has offered up some more information about what, exactly, th...

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with this event. For further details see: Alexion Pharmaceuticals (ALXN) Presents At J.P.Morgan Healthcare Conference - Slideshow